June 8, 2023
- NOT-HL-23-096 - Notice of Early Expiration and Reissuance of NOT-HL-22-010 "Notice of Special Interest (NOSI): Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups"
- May 25, 2023 - Updated Notice of Information for HIV research priorities at the National Heart, Lung, and Blood Institute. See Notice NOT-HL-23-088.
- January 31, 2022 - Notice of Special Interest (NOSI): Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups.See Notice NOT-HL-22-010 - EXPIRED.
- May 05, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185.
National Heart, Lung, and Blood Institute (NHLBI)
The purpose of this Notice is to inform potential applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in supporting analysis of barriers to care and risk of HIV-associated comorbidities among disproportionally vulnerable and affected population groups of people living with or at risk for HIV infection. This Notice replaces the former NOT-HL-22-010.
Background
The HIV/AIDS pandemic is an ongoing public health challenges. While current anti-retrovial therapy (ART) can control HIV replication, prevent AIDS, and contribute to the prolonged life of individuals living with HIV, ending the HIV epidemic will require prevention, diagnostic and treatment services that include all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance.
The HIV-related disparities and health care inequities that contribute to heightened risk of HIV-related Heart, Lung, Blood and Sleep (HLBS) disorders are important and understudied research areas. This NOSI encourages applications to perform research that will advance our understanding of barriers to care and other risk factors that contribute to HIV-associated comorbidities among disproportionally affected population groups including gay, bisexual, and other men who have sex with men, in particular Black, Latino, and American Indian/Alaska Native men; Black women; transgender women; reproductive aged-women, people in the 13 24 year age group; and people who inject drugs. Geographically, affected populations include people who live in 57 jurisdictions prioritized for the Ending the HIV Epidemic (EHE) initiative including 48 counties plus Washington, DC and San Juan, Puerto Rico, as well as seven Southern and Central U.S. states with substantial number of HIV diagnoses in rural areas.
Research Objectives
NHLBI is interested in receiving applications that incorporate interdisciplinary research collaborations, particularly between established and junior investigators. Specific areas of research interest include, but are by no means limited to:
- Increased HIV awareness in populations that are disproportionally affected by HIV-related HLBS disorders.
- Increased uptake of pre-exposure prophylaxis (PrEP) in populations that are disproportionally affected by HIV-related HLBS disorders.
- Enhanced opportunities for HIV testing and diagnosis in disproportionately at-risk populations for HIV-related HLBS disorders that are currently being missed.
- Improved HIV care retention within affected populations, including treatment for HIV-related HLBS co-morbidities.
- Syndemic connections between HIV-related HLBS co-morbidities with mental health, experience of violence and other types of traumas, alcohol and substance use, and/or infectious diseases.
While applications in response to this NOSI must be submitted under PA-20-185, clinical trials not allowed, NHLBI accepts clinical trials through separate NOFOs with specific requirements. Please see https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization for details.
Application and Submission Information
This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through May 7, 2025. No applications will be accepted on or after May 8, 2025.
Submit applications for this initiative using the following notice of funding opportunity (NOFO) or any reissue of this announcement.
- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
All instructions in the SF424 (R&R) Application Guide and the NOFO used for submission must be followed, with the following additions:
- For funding consideration, applicants must include NOT-HL-23-089 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:
Scientific/Research Contact(s)
Mary Y. Masterson, MS, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-6113
Email: Mary.Masterson@nih.gov
Emmanuel F. Mongodin, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-5968
Email: emmanuel.mongodin@nih.gov
Peer Review Contact(s)
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Financial/Grants Management Contact(s)
Fatima Kamara
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-7916
Email: fatima.kamara@nih.gov
and Human Services (HHS)
